{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-022603","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.345578+00:00","generated_at":"2026-05-16T19:49:42.119063+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cocrystal Pharma Reports Q3 2025 Net Loss of $2.0M, Provides Norovirus and Influenza Program Updates","bullets":["Received FDA IND clearance for CDI-988 as norovirus preventive and treatment; Phase 1b challenge study expected to begin Q1 2026.","Granted NIH SBIR award of $500,000 for influenza A/B replication inhibitor program.","Q3 2025 R&D expenses $954,000 vs $3.2M in Q3 2024; net loss $2.0M ($0.19 per share) vs $4.9M ($0.49 per share) year-over-year.","Raised $4.7M in registered direct offering in September 2025 and $1.03M in private placement in October 2025.","CC-42344 Phase 2a study completed; showed favorable safety, no SAEs; efficacy not reported due to trial conduct issues."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-022603","json":"https://secwatch.observer/filing/0001493152-25-022603.json","markdown":"https://secwatch.observer/filing/0001493152-25-022603.md","text":"https://secwatch.observer/filing/0001493152-25-022603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225022603/0001493152-25-022603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225022603/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T19:49:42.119063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}